[HTML][HTML] Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication

ZY Low, AJW Yip, SK Lal - Biochimica et Biophysica Acta (BBA)-Molecular …, 2022 - Elsevier
Ivermectin (IVM) is an FDA approved macrocyclic lactone compound traditionally used to
treat parasitic infestations and has shown to have antiviral potential from previous in-vitro …

SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376

E Heilmann, F Costacurta, SA Moghadasi… - Science translational …, 2022 - science.org
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first
protease inhibitor specifically developed against the SARS-CoV-2 protease 3CLpro that has …

[HTML][HTML] Phytochemicals in drug discovery—A confluence of tradition and innovation

P Chihomvu, A Ganesan, S Gibbons… - International Journal of …, 2024 - mdpi.com
Phytochemicals have a long and successful history in drug discovery. With recent
advancements in analytical techniques and methodologies, discovering bioactive leads from …

Genetic Surveillance of SARS-CoV-2 Mpro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid

JT Lee, Q Yang, A Gribenko, BS Perrin Jr, Y Zhu… - Mbio, 2022 - Am Soc Microbiol
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to represent a
global health emergency as a highly transmissible, airborne virus. An important coronaviral …

Discovery of SARS-CoV-2 M pro peptide inhibitors from modelling substrate and ligand binding

HTH Chan, MA Moesser, RK Walters, TR Malla… - Chemical …, 2021 - pubs.rsc.org
The main protease (Mpro) of SARS-CoV-2 is central to viral maturation and is a promising
drug target, but little is known about structural aspects of how it binds to its 11 natural …

The H163A mutation unravels an oxidized conformation of the SARS-CoV-2 main protease

N Tran, S Dasari, SAE Barwell, MJ McLeod… - Nature …, 2023 - nature.com
The main protease of SARS-CoV-2 (Mpro) is an important target for developing COVID-19
therapeutics. Recent work has highlighted Mpro's susceptibility to undergo redox-associated …

A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron …

J Pérez-Vargas, LJ Worrall, AD Olmstead… - Emerging microbes & …, 2023 - Taylor & Francis
Antivirals with broad coronavirus activity are important for treating high-risk individuals
exposed to the constantly evolving SARS-CoV-2 variants of concern (VOCs) as well as …

Modulation of the monomer-dimer equilibrium and catalytic activity of SARS-CoV-2 main protease by a transition-state analog inhibitor

NT Nashed, A Aniana, R Ghirlando… - Communications …, 2022 - nature.com
The role of dimer formation for the onset of catalytic activity of SARS-CoV-2 main protease
(MProWT) was assessed using a predominantly monomeric mutant (MProM). Rates of …

[HTML][HTML] An overview of potential inhibitors targeting non-structural proteins 3 (PLpro and Mac1) and 5 (3CLpro/Mpro) of SARS-CoV-2

F Yan, F Gao - Computational and structural biotechnology journal, 2021 - Elsevier
There is an urgent need to develop effective treatments for coronavirus disease 2019
(COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS …

[HTML][HTML] Allosteric binding sites of the SARS-CoV-2 main protease: potential targets for broad-spectrum anti-coronavirus agents

L Alzyoud, MA Ghattas, N Atatreh - Drug Design, Development and …, 2022 - ncbi.nlm.nih.gov
The current pandemic caused by the COVID-19 disease has reached everywhere in the
world and has affected every aspect of our lives. As of the current data, the World Health …